IVVD

Invivyd, Inc. (IVVD) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Invivyd, Inc. is a biopharmaceutical company focused on monoclonal antibody therapies for viral infectious diseases. The company's primary revenue source is PEMGARDA (pemivibart), which holds an Emergency Use Authorization (EUA) for COVID-19 prevention in immunocompromised patients. The EUA is set to terminate on June 29, 2027, following a June 30, 2026 announcement by the U.S. Department of Health and Human Services regarding the termination of the pandemic declaration. The company is advancing its next-generation candidate, VYD2311, through Phase 3 clinical trials (DECLARATION and LIBERTY) with top-line data expected in Q3 2026.

Key Financial Metrics (Six Months Ended June 30, 2026)

Note: Gross margin for product revenue is approximately 92% ($25.7M gross profit on $28.0M revenue), though management notes that pre-EUA manufacturing costs were expensed rather than capitalized, which would have reduced margins to ~80% if capitalized.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by 21% year-over-year (from $23.1M to $28.0M) due to increased demand for PEMGARDA.
• Expense Surge: Operating expenses more than doubled, rising from $55.1M to $117.0M.
  • R&D: Increased by 197% (from $20.2M to $60.1M), driven primarily by a $40.6M increase in costs for the VYD2311 Phase 3 clinical trials (DECLARATION and LIBERTY).
  • SG&A: Increased by 64% (from $33.3M to $54.6M), attributed to higher headcount, professional fees, and sales/marketing costs.
• Liquidity: Cash balances decreased by $66.6M during the period, primarily due to operating losses, partially offset by $19.4M in financing proceeds from an At-The-Market (ATM) offering.

Outlook, Risks, and Contingencies

• Going Concern Warning: The company has concluded there is substantial doubt about its ability to continue as a going concern. Based on current plans and excluding future financing, cash is insufficient to fund operations beyond one year from the filing date.
• PEMGARDA EUA Termination: The EUA for the company's only revenue-generating product will terminate on June 29, 2027. The company is in dialogue with the FDA regarding a Biologics License Application (BLA) but faces uncertainty regarding approval timing and potential inventory obsolescence.
• Nasdaq Listing Compliance: On July 23, 2026, the company received notice from Nasdaq that its stock price closed below $1.00 for 30 consecutive days, failing the minimum bid price requirement. The company has until January 19, 2027, to regain compliance.
• Debt Facility: A $30M term loan facility with Silicon Valley Bank exists, but no amounts have been drawn as of June 30, 2026, because the company has not yet met the required net product revenue milestones.
• Capital Needs: The company expects to require additional funding through equity offerings, debt, or collaborations to sustain operations and advance clinical programs.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash exhaustion and the status of any new financing discussions.
• VYD2311 Clinical Data: Monitor the release of top-line data for the DECLARATION and LIBERTY trials (expected Q3 2026) as this is critical for future valuation and regulatory approval.
• PEMGARDA BLA Strategy: Assess the progress of FDA discussions regarding the transition from EUA to full approval before the June 2027 deadline.
• Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid requirement to avoid delisting.
• Inventory Valuation: Review potential risks of inventory write-downs for PEMGARDA if the EUA terminates without a successful BLA approval.